Trial reportBMC public health2025
Diabetes prevention in the Caribbean using lifestyle intervention and Metformin escalation (LIME): results from a quasi-experimental study.
Trial report in BMC public health, 2025. The graph read 1 number from its abstract, feeding 1 cell of the map, but none could be read as for or against, so it casts no vote. It reports registered trial NCT03258723. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
At the 6-month follow-up, there was a significant reduction in average HbA1c from 6.19% to 5.95% (p < 0.001), average weight from 86.7 kg to 85 kg (p < 0.001), with a reduction in added sugar intake from 7.3 tsp/day to 3.8 tsp/day (p < 0.0001) but no significant change in physical activity level or fruit and vegetable intake.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Diet, exercise & lifestyle×quality of life & behaviour
No readable resultOpen on the map →What to test next →No other readable study in this cell yet. This paper is the evidence.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diabetes Prevention With Lifestyle Intervention and Metformin Escalation
Open the trial in the graphWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
backgroundThe Caribbean region suffers from a high burden of diabetes and diabetes-associated mortality. Despite the evidence for diabetes prevention programs, there have been very few such initiatives in the region. To address this gap, we describe the effectiveness and implementation of the Lifestyle Intervention and Metformin Escalation (LIME) Clinical Trial in reducing the risk of diabetes among individuals with pre-diabetes in the Caribbean.
methodsLIME is a quasi-experimental pre-post study that took place between 2018 and 2021. LIME recruited individuals with high-risk pre-diabetes (hemoglobin A1c (HbA1c) between 6.0 and 6.4%) across clinical sites in Barbados, Trinidad and Tobago, Puerto Rico, and the US Virgin Islands. Eligible participants were enrolled in a 6-week lifestyle modification workshop. Six months later, individuals who did not lose at least 5% of their bodyweight or had an HbA1c of 6% or higher were prescribed metformin medication. The primary outcome was a change in HbA1c at 6- and 12-months. Paired t-test and McNemar's test were used to examine change in primary outcome. Implementation outcomes of reach, adoption, and implementation fidelity were assessed using programmatic data.
resultsOf 914 individuals screened, 211 (23%) had high-risk pre-diabetes. Of those, 114 enrolled in the study (54% Reach). At the 6-month follow-up, there was a significant reduction in average HbA1c from 6.19% to 5.95% (p < 0.001), average weight from 86.7 kg to 85 kg (p < 0.001), with a reduction in added sugar intake from 7.3 tsp/day to 3.8 tsp/day (p < 0.0001) but no significant change in physical activity level or fruit and vegetable intake. Reduction in HbA1c (6.19% to 5.67%, p < 0.0001) and weight (85.1 kg to 83.7 kg, p = 0.0149) was maintained at 12 months. Trained facilitators variably engaged in leading workshops (adoption 25%-100%), and were 100% adherent to the protocol (fidelity).
conclusionLIME is an effective diabetes prevention intervention for individuals with pre-diabetes in the Caribbean. Future work should investigate approaches to improve reach (eligible participant engagement) and adoption (participation of trained facilitators), and report on cost-effectiveness to inform scale-up of the intervention.
trial registrationclinicaltrials.gov NCT03258723 (23/08/2017).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.